Evidence map›Paper›PMID 34028749›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2021

Fibrosis on a Chip for Screening of Anti-Fibrosis Drugs.

Mohammadnabi Asmani, Ruogang Zhao

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. The evolution ofEuropean respiratory review : an official journal of the European Respiratory Society · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Mohammadnabi AsmaniDepartment of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, NY, USA.
Ruogang ZhaoDepartment of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, NY, USA. rgzhao@buffalo.edu.
University at Buffalo, State University of New York · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic pathological disorder that targets alveoli interstitial tissues and is characterized by the progressive stiffening of alveolar membrane. The median survival rate of the patients with IPF is less than 5 years. Currently, IPF has no cure and there are few options to alleviate the progress of this disease. A critical roadblock in developing new anti-fibrosis therapies is the absence of reliable cell based in vitro models that can recapitulate the progressive features of this disease. Here a novel fibrotic microtissue on a chip system is created to model the fibrotic transition of the lung interstitial tissue and the effect of anti-fibrosis drugs on such transitions. This system will not only help to expedite the efficacy analysis of anti-fibrotic therapies but also help to unveil their potential mode of action.

Indexed as

Cells, CulturedDrug Evaluation, PreclinicalFibroblastsHumansIdiopathic Pulmonary FibrosisIndolesLab-On-A-Chip DevicesModels, BiologicalPyridonesIndolesnintedanibpirfenidonePyridonesAnti-fibrosis therapyDrug screeningLung on a chipMicrotissue arrayNintedanibPirfenidonePulmonary fibrosisStiffness, and contractile forceTissue mechanics

Identifiers

PMID34028749
OpenAlexW3164791731

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.